Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans

Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides

(2015) Richard S. Geary et al.   ADVANCED DRUG DELIVERY REVIEWS

Mipomersen, an Antisense Oligonucleotide to Apolipoprotein B-100, Reduces Lipoprotein(a) in Various Populations With HypercholesterolemiaSignificance

(2015) Raul D. Santos et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

First data from the German Lipoprotein Apheresis Registry (GLAR)

(2015) Volker J.J. Schettler et al.   ATHEROSCLEROSIS SUPPLEMENTS

The impact of lipoprotein apheresis in patients with refractory angina and raised lipoprotein(a): Objectives and methods of a randomised controlled trial

(2015) Tina Z. Khan et al.   ATHEROSCLEROSIS SUPPLEMENTS

Effects of Lipoprotein apheresis on the Lipoprotein(a) levels in the long run

(2015) E. Groß et al.   ATHEROSCLEROSIS SUPPLEMENTS

Clinical and Preclinical Pharmacokinetics and Pharmacodynamics of Mipomersen (Kynamro®): A Second-Generation Antisense Oligonucleotide Inhibitor of Apolipoprotein B

(2015) Richard S. Geary et al.   CLINICAL PHARMACOKINETICS

‘LDL-C’ = LDL-C + Lp(a)-C

(2015) Calvin Yeang et al.   CURRENT OPINION IN LIPIDOLOGY

Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis

(2015) Romain Capoulade et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial

(2015) G Kees Hovingh et al.   LANCET

Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study

(2015) Sotirios Tsimikas et al.   LANCET

Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis

(2015) Harry R. Büller et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia

(2015) Daniel Gaudet et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials

(2014) E. A. Stein et al.   EUROPEAN HEART JOURNAL

Dramatic fate of a young coronary heart disease patient rescued with specific lipoprotein(a) apheresis

(2014) Maya S. Safarova et al.   JOURNAL OF CLINICAL APHERESIS

Pro-Inflammatory Interleukin-1 Genotypes Potentiate the Risk of Coronary Artery Disease and Cardiovascular Events Mediated by Oxidized Phospholipids and Lipoprotein(a)

(2014) Sotirios Tsimikas et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Release and Capture of Bioactive Oxidized Phospholipids and Oxidized Cholesteryl Esters During Percutaneous Coronary and Peripheral Arterial Interventions in Humans

(2014) Amir Ravandi et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

The Severe Hypercholesterolemia Phenotype

(2014) Allan D. Sniderman et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)

(2014) Frederick J. Raal et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Targeting APOC3 in the Familial Chylomicronemia Syndrome

(2014) Daniel Gaudet et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeted delivery of antisense oligonucleotides to hepatocytes using triantennaryN-acetyl galactosamine improves potency 10-fold in mice

(2014) Thazha P. Prakash et al.   NUCLEIC ACIDS RESEARCH

Lipoprotein Apheresis in Patients With Maximally Tolerated Lipid-Lowering Therapy, Lipoprotein(a)-Hyperlipoproteinemia, and Progressive Cardiovascular Disease

(2013) Josef Leebmann et al.   CIRCULATION

Elevated lipoprotein (a), small apolipoprotein (a), and the risk of arterial ischemic stroke in North American children

(2013) N. A. Goldenberg et al.   HAEMATOLOGICA

Lipoprotein(a): resurrected by genetics

(2013) F. Kronenberg et al.   JOURNAL OF INTERNAL MEDICINE

Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a)

(2013) Gregor Leibundgut et al.   JOURNAL OF LIPID RESEARCH

MCP-1 binds to oxidized LDL and is carried by lipoprotein(a) in human plasma

(2013) Philipp Wiesner et al.   JOURNAL OF LIPID RESEARCH

Mipomersen, an Apolipoprotein B Synthesis Inhibitor, Reduces Atherogenic Lipoproteins in Patients With Severe Hypercholesterolemia at High Cardiovascular Risk

(2013) Gregory S. Thomas et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Elevated Lipoprotein(a) and Risk of Aortic Valve Stenosis in the General Population

(2013) Pia R. Kamstrup et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Genetic Associations with Valvular Calcification and Aortic Stenosis

(2013) George Thanassoulis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mechanisms of Lipoprotein(a) Pathogenicity

(2012) J. David Spence et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B

(2012) Stanley T. Crooke et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Apolipoprotein B Synthesis Inhibition With Mipomersen in Heterozygous Familial Hypercholesterolemia

(2012) Evan A. Stein et al.   CIRCULATION

Lipoprotein(a)

(2012) Joseph B. Dubé et al.   CURRENT OPINION IN LIPIDOLOGY

Clinical pharmacokinetics of second generation antisense oligonucleotides

(2012) Rosie Z Yu et al.   Expert Opinion on Drug Metabolism & Toxicology

Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions

(2012) Rogier A. van Dijk et al.   JOURNAL OF LIPID RESEARCH

Oxidation-Specific Biomarkers, Prospective 15-Year Cardiovascular and Stroke Outcomes, and Net Reclassification of Cardiovascular Events

(2012) Sotirios Tsimikas et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Randomized, Placebo-Controlled Trial of Mipomersen in Patients with Severe Hypercholesterolemia Receiving Maximally Tolerated Lipid-Lowering Therapy

(2012) Mary P. McGowan et al.   PLoS One

Antisense Oligonucleotide Lowers Plasma Levels of Apolipoprotein (a) and Lipoprotein (a) in Transgenic Mice

(2011) Esther Merki et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Oxidation-Specific Biomarkers, Lipoprotein(a), and Risk of Fatal and Nonfatal Coronary Events

(2010) Sotirios Tsimikas et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

(2010) Frederick J Raal et al.   LANCET

Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease

(2010) Christopher P. Cannon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antisense oligonucleotide pharmacokinetics and metabolism

(2009) Richard S Geary   Expert Opinion on Drug Metabolism & Toxicology

Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality

(2009)   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease

(2009) Robert Clarke et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antisense Oligonucleotide Directed to Human Apolipoprotein B-100 Reduces Lipoprotein(a) Levels and Oxidized Phospholipids on Human Apolipoprotein B-100 Particles in Lipoprotein(a) Transgenic Mice

(2008) Esther Merki et al.   CIRCULATION

A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma

(2008) Claes Bergmark et al.   JOURNAL OF LIPID RESEARCH

Extreme Lipoprotein(a) Levels and Risk of Myocardial Infarction in the General Population

(2007) Pia R. Kamstrup et al.   CIRCULATION